Gabapentin Tablet, Film Coated
Product Images NDC 50090-6854

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6854). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gabapentin Fig1)

An illustration depicting the formula for calculating creatinine clearance (CLCr), showing the variables of age, weight, serum creatinine, and an adjustment factor for female patients.*

FDA Label Image

Fig2 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over 8 weeks. Two groups are depicted: Placebo (open circles) maintaining higher pain scores near 6, and Gabapentin 3600 mg/day (solid triangles) showing a decrease from about 6 to below 4. The x-axis is labeled weeks from baseline to 8, and the y-axis shows mean pain score from 0 to 10. A 4-week dose titration period and 4-week fixed dose period are marked.*

FDA Label Image

Fig3 (Gabapentin Fig3)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to week 7, and the y-axis represents mean pain scores ranging from 0 to 10. The graph includes three lines for Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, illustrating pain score trends during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Fig4 (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders in two studies for placebo (PBO) and gabapentin (GBP) at different dosages (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2). The graph shows higher responder rates for gabapentin groups compared to placebo, with statistical significance indicated.*

FDA Label Image

Fig5 (Gabapentin Fig5)

A scatter plot chart showing responder rate differences (%) from placebo by daily dose (mg) of gabapentin in adjunctive therapy studies for patients aged 12 and older with partial seizures. The chart compares results across three studies, labeled Study a, Study b, and Study c, with responder rate difference on the y-axis and daily dose (600 to 1800 mg) on the x-axis.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

Label Image (Lbl500906854)

Gabapentin 600 mg film-coated tablets manufactured by A-S Medication Solutions. The label includes storage instructions to keep the product at 68 to 77 degrees Fahrenheit. The package contains 90 tablets for oral administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.